--- canonical_url: https://www.stockexpertai.com/earnings/ci last_updated: 2026-08-12T06:13:07.883Z --- # Cigna Corporation (CI) Q1 FY2027 Earnings Preview > This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-08-12T06:13:07.419Z. Educational tool, not investment advice. --- ## Quick Summary | Field | Value | Source | |---|---|---| | Price | $273.87 (▼ -1.63%) | fmp:quote | | Market Cap | $72.4B | fmp:profile | | 52w range | $239.51 – $315.47 | fmp:quote | | Earnings | Thu 29 Oct | fmp:earnings-history | | EPS estimate | $7.50 (-4% YoY) | fmp:earnings-estimate | | Revenue estimate | $72.7B | fmp:earnings-estimate | | Beat streak | 6/4 | fmp:earnings-history | | Rating | A- (overall 4/5) | fmp:ratings | | Analyst median target | $340 (+24.1% upside) | fmp:price-target-consensus | | MoonshotScore | 30/100 | derived | | Council | 2/6 bullish | derived | | Munger verdict | Fairly Valued | derived | ## Cigna Corporation — Q1 FY2027 Expectations Q1 consensus: revenue $72.7B^{[FMP est]}, EPS $7.50^{[FMP est]}. 6 consecutive quarters of beat^{[FMP earnings]}. ## Quick Take **Score:** A- · **Stance:** BUY · **Council:** 2/6 · **Moonshot:** 30 = MoonshotScore 30^{[multi-pillar formula]} + Council 2/6^{[6-lens rule]}. Form 4: 0 transactions^{[FMP Form 4]}. ## Watchlist (4 metrics) ### 1. Evernorth Specialty Growth Evernorth's Specialty and Care Services business delivered strong adjusted earnings growth of 20% in Q1 2026, driven by attractive volume growth and demand for specialty drugs. > "Specialty and Care Services showed strong growth with pretax adjusted earnings up 20% to $1.1 billion. This performance reflects continued momentum in our fastest-growing business, including strong demand for specialty drugs and increased biosimilar and specialty generic adoption, which are key levers for delivering affordability and value to patients and clients." > — Ann Dennison, CFO, Investor Focus · Q1 FY2026 ### 2. Fy26 Eps Guidance Raise Cigna Group has raised its full year 2026 adjusted EPS outlook to at least $30.35, reflecting strong first-quarter performance and disciplined execution. > "With our performance, we are raising our full year 2026 adjusted EPS outlook to at least $30.35, reflecting our disciplined approach and steady execution in an operating environment that continues to be shaped by many forces." > — David Cordani, CEO, Expectation / Guide · Q1 FY2026 ### 3. Ai Driven Personalization Affordability Cigna is leveraging AI and advanced analytics to enhance customer experience, drive affordability, and personalize health services, leading to a 20% drop in inbound calls for digitally eligible customers. > "The combination of our AI tools and contact centers and improved customer digital experiences led to a 20% drop in total inbound calls for digitally eligible customer in our Cigna Healthcare U.S. employer business and a 25% reduction for pharmacy benefit services members when compared to just 2 years ago." > — Brian Evanko, President and COO, Investor Focus · Q1 FY2026 ### 4. Individual Exchange Exit Cigna plans to exit its individual exchange business at the end of 2026 to sharpen focus on core platforms where it can deliver differentiated value. > "First, we are planning to exit our individual exchange business at the end of this year. We did not make this decision lightly and appreciate the importance of ensuring patients have continuity through the transition." > — Brian Evanko, President and COO, Investor Focus · Q1 FY2026 ## MoonshotScore Pillars | Pillar | Score | Level | Evidence | |---|---|---|---| | Revenue Growth | 1.0 | weak | Q2 vs Q3: growth slowing (+2.8%, below threshold) | | Gross Margin | 2.0 | weak | Q2: low margin (20.9%, capital-intensive or commodity) | | Operating Leverage | 0.0 | weak | op margin weak (3.7%, under pressure) | | Cash Runway | 3.0 | weak | FCF negative ($-0.7B, external financing needed) | | R&D Intensity | 3.0 | weak | low R&D investment (0.0%, weak innovation) | | Price Momentum | 4.0 | medium | RSI 42.6 weak momentum, 50d below | | News Sentiment | 8.0 | strong | strong buy consensus (83%) | **Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula. ## Council (7-Lens) | Name | Stance | Context | |---|---|---| | Ray Dalio | bull | macro · target upside +24.1% | | Ken Griffin | bear | flow · 50d MA below | | Jim Simons | neutral | quant · RSI 43 | | Klarman | neutral | value · target upside +24.1% | | Buffett | bull | quality · ROE score 4/5 | | Munger | neutral | valuation · target upside +24.1% | **Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr. ## Munger Lens - **Verdict:** Fairly Valued - **Financial Health:** Strong - **Margin of Safety:** Moderate - **Interest Coverage:** Adequate - **ROIC vs WACC:** Healthy **Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget. ## Technical Levels - **RSI(14):** 42.6 — momentum zayıf — oversold yakınında değil ama alıcı baskısı az - **50d MA:** $286 — hisse %4.1 altında — kısa vadeli direnç - **200d MA:** $279 — hisse %1.9 altında — uzun vadeli baskı - **Volume (10d):** -41% ## Past Performance (4 Quarters) | Quarter | EPS Actual | EPS Estimate | Result | Reaction | |---|---|---|---|---| | Q3 FY25 | $7.83 | $7.64 | BEAT | -1.1% | | Q4 FY25 | $8.08 | $7.88 | BEAT | +2.6% | | Q1 FY26 | $7.79 | $7.60 | BEAT | -2.6% | | Q2 FY26 | $7.78 | $7.60 | +2.4% EPS | -3.0% | Q1 (April 30, 2026): EPS $7.78 vs $7.60 est^[FMP], +2.4% beat. D+1 movement: -3.0%^{[FMP D+1]}. Decline despite beat — market reacted to guidance, not numbers. ## 3 Scenarios ### Scenario A · Beat **Q1 EPS > $7.50 + CapEx discipline** Threshold: EPS > $7.50^{[FMP est]}. Target: Break above median target $340^{[FMP target]}; high target $400^[FMP] upper bound. ### Scenario B · In-Line **EPS ≈ $7.50 + CapEx < $297.0M** Threshold: EPS ≈ $7.50^{[FMP est]}, Q1 CapEx < $297.0M^[FMP]. Target: Consolidation in the band between current $274^[FMP] and median $340^[FMP]. ### Scenario C · Miss **EPS < $7.27 or CapEx ≥ $297.0M** Threshold: EPS < $7.27^{[FMP est×0.97]}. Target: Current $274 below SMA200 $279^[FMP], if rejection continues, $237^[derived] support activates. ## Risk Notes ### Primary segment below threshold Q1: EPS $7.78 vs $7.60 beat^[FMP], stock -3.0% D+1^[FMP]. ### Backlog concentration No RPO/backlog concentration disclosed in Q1 earnings call. ### Insider trading Form 4 data is marked in the table — this page does not generate assumptions for this stock. | Executive | Action | Amount | Date | |---|---|---|---| **Net:** — (0 transactions · 0 sells · 0 buys) · Q2 FY26 ### CapEx shock Q1 CapEx $297.0M^{[FMP cashflow]}. Q1 op margin 3.7%^{[FMP op margin]} — this level in Q1 is sensitive to CapEx revision risk. ## Wall Street Consensus - **Median target:** $340 (+24.1% upside vs current $274) - **High / Low:** $400 / $302 - **Buy / Hold / Sell:** 20 / 4 / 0 - **Analyst count:** 12 (last quarter), 87 all-time ## Additional Transcript Insights ### 1. fy26_eps_guidance_raise **Claim:** Cigna Group has raised its full year 2026 adjusted EPS outlook to at least $30.35, reflecting strong first-quarter performance and disciplined execution. **Evidence (transcript):** "With our performance, we are raising our full year 2026 adjusted EPS outlook to at least $30.35, reflecting our disciplined approach and steady execution in an operating environment that continues to be shaped by many forces." **Numbers:** 2026, $30.35 ### 2. individual_exchange_exit **Claim:** Cigna plans to exit its individual exchange business at the end of 2026 to sharpen focus on core platforms where it can deliver differentiated value. **Evidence (transcript):** "First, we are planning to exit our individual exchange business at the end of this year. We did not make this decision lightly and appreciate the importance of ensuring patients have continuity through the transition." **Numbers:** 2026, 2027 ### 3. evicore_strategic_review **Claim:** Cigna is initiating a strategic review of alternatives for eviCore, aiming to maximize long-term value while the industry progresses on standardizing prior authorization services. **Evidence (transcript):** "Second, as our industry continues to make strong progress on standardizing and automating prior authorization services, we have decided to initiate a strategic review of alternatives for eviCore." **Numbers:** — ### 4. evernorth_specialty_growth **Claim:** Evernorth's Specialty and Care Services business delivered strong adjusted earnings growth of 20% in Q1 2026, driven by attractive volume growth and demand for specialty drugs. **Evidence (transcript):** "Specialty and Care Services showed strong growth with pretax adjusted earnings up 20% to $1.1 billion. This performance reflects continued momentum in our fastest-growing business, including strong demand for specialty drugs and increased biosimilar and specialty generic adoption, which are key levers for delivering affordability and value to patients and clients." **Numbers:** 20%, $1.1 billion ### 5. signature_pharmacy_model **Claim:** Cigna's new transformative rebate-free pharmacy service model, "Signature," is resonating with clients by offering the lowest out-of-pocket costs for consumers and greater predictability. **Evidence (transcript):** "First, our forward-thinking innovation is resonating for its focus on the consumer, offering the lowest out-of-pocket cost at the pharmacy counter and helping clients navigate through a very complex and fluid external environment." **Numbers:** — ### 6. ai_driven_personalization_affordability **Claim:** Cigna is leveraging AI and advanced analytics to enhance customer experience, drive affordability, and personalize health services, leading to a 20% drop in inbound calls for digitally eligible customers. **Evidence (transcript):** "The combination of our AI tools and contact centers and improved customer digital experiences led to a 20% drop in total inbound calls for digitally eligible customer in our Cigna Healthcare U.S. employer business and a 25% reduction for pharmacy benefit services members when compared to just 2 years ago." **Numbers:** 20%, 25%, 2 --- *Data source: FMP (live query, 2026-08-12), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*